PSORITUS - Secukinumab study in PSOriasis exploring pruRITUS intensity and lesional biomarkers (CAIN457ADE03)
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102725
下载链接
链接失效反馈官方服务：
资源简介：
Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (300 mg) during a 16 week open-label run-in phase followed by a 16 week randomized, double-blind, placebo-controlled withdrawal phase. Psoriasis patients received 300 mg subcutaneous secukinumab during a 16 week open-label run-in phase followed by 16 week randomized, double-blind, placebo-controlled withdrawal phase
创建时间：
2021-07-25
